Study of *hTERT* and Histone 3 Mutations in Medulloblastoma

Marta Viana-Pereira^{a, b} Gisele Caravina Almeida^d
João Norberto Stavale^g Susana Malheiro^h Carlos Clara^e Patrícia Lobo^c
José Pimentel^c Rui Manuel Reis^{a, b, f}

^aLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga,

^bICVS/3B's – PT Government Associate Laboratory, Braga/Guimarães, and ^cLaboratory of Neuropathology,

Santa Maria Hospital, Institute of Molecular Medicine, Lisbon Faculty of Medicine, Lisbon, Portugal; Departments of

^dPathology and ^eNeurosurgery and ^fMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos, and
Departments of ^gPathology and ^hNeurology and Neurosurgery, Federal University of São Paulo, São Paulo, Brazil

Key Words

hTERT · Mutations · Medulloblastoma · Biomarkers

Abstract

Hotspot activating mutations of the telomerase reverse transcriptase (*hTERT*) promoter region were recently described in several tumor types. These mutations lead to enhanced expression of telomerase, being responsible for telomere maintenance and allowing continuous cell division. Additionally, there are alternative telomere maintenance mechanisms, associated with histone H3 mutations, responsible for disrupting the histone code and affecting the regulation of transcription. Here, we investigated the clinical relevance of these mechanistically related molecules in medulloblastoma. Sixty-nine medulloblastomas, formalin fixed and paraffin embedded, from a cohort of patients aged 1.5–70 years, were used to investigate the hotspot mutations of the *hTERT* promoter region, i.e. *H3F3A* and *HIST1H3B*, using Sanger sequencing. We successfully sequenced *hTERT* in all 69 medulloblastoma samples and identified a total of 19 mutated cases (27.5%). c.-124:G>A and c.-146:G>A mutations were detected, respectively, in 16 and 3 samples. Similar to previous

reports, *hTERT* mutations were more frequent in older patients ($p < 0.0001$), being found only in 5 patients <20 years of age. In addition, *hTERT*-mutated tumors were more frequently recurrent ($p = 0.026$) and *hTERT* mutations were significantly enriched in tumors located in the right cerebellar hemisphere ($p = 0.039$). No mutations were found on the *H3F3A* or *HIST1H3B* genes. *hTERT* promoter mutations are frequent in medulloblastoma and are associated with older patients, prone to recurrence and located in the right cerebellar hemisphere. On the other hand, histone 3 mutations do not seem to be present in medulloblastoma.

© 2016 S. Karger AG, Basel

Introduction

Shortening of telomeres is a natural mechanism that occurs during the replication of somatic cells, and is responsible for cell aging and replicative senescence [1, 2]. One major mechanism of telomere length control is associated with the activity of the telomerase enzyme [1, 2]. The catalytic subunit of this enzyme is encoded by the telomerase reverse transcriptase (*hTERT*) gene and mod-

ulates telomerase activity [2, 3]. Although telomerase is normally silenced in somatic cells, it is active in male germ cells, activated lymphocytes, stem cell populations and during development [4–6]. In the large majority of human cancers, abnormal telomerase reactivation is observed, leading to telomere maintenance and limitless proliferative potential [7–9].

Hotspot activating mutations were recently described in the *hTERT* promoter region in a variety tumor types, including medulloblastomas (20%) and glioblastomas (83%) among many others [10–12]. These mutations are located in 2 positions, c.-124:G>A and c.-146:G>A, and are thought to be the main biological mechanism responsible for telomerase overexpression [13, 14]. The functional consequence of the presence of promoter mutations was initially associated with the creation a new binding motif for E-twenty-six (ETS) transcription factors and ternary complex factors (TCFs) near the transcription start, leading to an increased transcription of the *hTERT* promoter of at least 2-fold, as assessed by reporter assays [13, 14]. Recently, it was also demonstrated that the occurrence of these mutations leads to the recruitment of the GABP transcription factor, and the activation of transcription and aberrant expression of *hTERT* in several cancers [15]. In addition to these mutations, a common functional single nucleotide polymorphism (SNP), rs2853669, located in the *hTERT* promoter has been shown to influence the prognostic value of the mutations mentioned in gliomas and bladder and renal cell carcinomas [16].

Alternative lengthening of telomeres (ALT) pathways has also been described, being present in 15% of cancers. Inactivating *ATRX* mutations, associated with histone H3 mutations, were described in tumors with ALT phenotype, including 1.5% of medulloblastoma [17]. These mutations were reported to be responsible for disrupting the histone code and affecting the regulation of transcription [18]. Mutations in histone 3 (*H3F3A*, encoding H3.3 and *HIST1H3B*, encoding H3.1) have been reported in higher frequencies in pediatric gliomas of different histologies, but have not been extensively studied in medulloblastoma [18–20].

In this work, we investigated the clinical relevance of these important regulators in medulloblastoma, confirming that *hTERT* promoter mutations are a frequent event in medulloblastoma. These mutations were associated with older age, tumor recurrence and tumors from the right cerebellar hemisphere. On the other hand, histone mutations do not seem to be present in this type of brain tumor.

Material and Methods

Tumor Samples and DNA Isolation

Formalin-fixed, paraffin-embedded (FFPE) medulloblastoma samples from 68 patients, i.e. 68 primary tumors and 1 recurrence (with a matched primary tumor sample) aged 1.5–70 years, were obtained after approval by local and multicenter ethical review committees at the Laboratory of Neuropathology, Hospital of Santa Maria (CHLN), Lisbon, Portugal, and the Federal University of São Paulo, São Paulo, and Barretos Cancer Hospital, Barretos, Brazil. All the samples enrolled in the study were unlinked and unidentified from their donors. Due the retrospective nature of the study, no written informed consent from patients was obtained. The presence of tumor tissue in the samples and the tumor histology was verified on an H&E-stained section by the pathologists J.N.S., J.P. and G.C.A.

DNA was isolated using the QIAamp DNA mini kit (Qiagen) according to the manufacturer's instructions and as previously reported [21].

Mutation Analysis

hTERT promoter mutations were screened using the primers previously described [22] that amplify the sites of the c.-124:G>A and c.-146:G>A mutations, as previously described [12, 23, 24].

Histone 3 hotspot regions previously identified [18, 19] were amplified with the following primers: *H3F3A* (forward: 5'-CATGGCTCGTACAAAGCAGA; reverse: 5'-CAAGAGAGACTTTGTCCCATTTTT) and *HIST1H3B* (forward: 5'-TTTCCTTTCC-TCCACAGACG; reverse: 5'-CGGTAACGGTGAGGCTTTT).

Amplification of PCR products was confirmed by gel electrophoresis. Subsequently, samples were Sanger-sequenced after PCR product purification with ExoStar (Invitrogen). Sequencing PCR was performed using the ABI PRISM 3730xL DNA analyzer (Applied Biosystems, USA) by STAB VIDA services (Portugal).

Statistical Analysis

All statistical tests were done in SPSS v20.0 (SPSS Inc.). Correlations between categorical values were done using the 2-tailed χ^2 test and the Fisher exact test. Continuous variables were assessed using the Mann-Whitney U test. Associations between *hTERT* mutational status and patients' overall survival were analyzed using the Kaplan-Meier method and the log-rank test. A p value of <0.05 was considered significant.

Results

hTERT Is Frequently Mutated in Medulloblastoma

We successfully sequenced *hTERT* in 69 FFPE medulloblastomas, corresponding to 68 primary tumors and 1 recurrence. Of these, 35 samples were from pediatric patients (1.5–17 years of age) and 32 from adults (>18 years); for an additional sample we could not confirm the age at diagnosis. We identified a total of 19 cases (27.5%) with *hTERT* promoter mutations (table 1). The c.-124:G>A mutation was detected in 16 samples, and the c.-146:G>A mutation (fig. 1) in 3 cases.

Table 1. Clinicopathological and molecular features of medulloblastoma

Sample No.	Gender/ age, years	Histology	OS, m	<i>hTERT</i> mutation	SNP rs2853669	H3.1	H3.3	Sample No.	Gender/ age, years	Histology	OS, m	<i>hTERT</i> mutation	SNP rs2853669	H3.1	H3.3
M1	M/11	classic	–	WT	AA	WT	WT	M47	F/10	classic	109	WT	–	–	WT
M3 ^a	M/35	classic	–	c.-124:GA	AG	WT	WT	M48	M/12	desmoplastic	101	c.-124:AA	–	WT	WT
M5	M/1.5	classic	–	WT	AG	–	WT	M49	M/18	classic	42	c.-124:GA	–	WT	WT
M7	F/70	classic	–	c.-124:GA	AA	WT	WT	M52	M/19	classic	94	WT	–	–	WT
M8	M/20	classic	–	c.-124:GA	–	WT	WT	M54	M/7	classic	68	WT	–	WT	WT
M9	F/26	classic	–	WT	–	WT	WT	M55	F/19	desmoplastic	66	c.-124:GA	AG	WT	WT
M12	F/1.5	classic	–	WT	–	WT	WT	M58	M/2	nodular	47	WT	AA	WT	WT
M13	M/21	desmoplastic	–	WT	–	WT	WT	M61	M/8	classic	73	WT	AA	WT	WT
M14	M/11	classic	–	WT	AA	WT	WT	M62	M/8	classic	20	WT	AA	WT	WT
M15	M/28	classic	–	c.-124:GA	AA	WT	WT	M66	M/16	classic	30	WT	AA	WT	WT
M16	M/34	classic	–	c.-124:GA	AA	WT	WT	M67	M/2	desmoplastic	2	WT	AA	WT	WT
M17	M/6	classic	–	WT	–	WT	WT	M68	M/5	classic	44	WT	AA	WT	WT
M18	F/24	classic	–	c.-124:GA	AA	WT	WT	M69	M/4	nodular	44	WT	AA	WT	–
M19	F/34	classic	–	WT	AA	WT	WT	M70	F/17	classic	42	WT	AG	WT	WT
M20	M/12	classic	–	WT	–	WT	WT	M74	M/18	desmoplastic	114	c.-146:AA	–	WT	WT
M22	F/16	classic	–	WT	–	–	WT	M75	F/21	classic	48	c.-124:GA	AG	WT	WT
M24	M/7	classic	–	WT	–	WT	WT	M76	F/20	classic	1	WT	AA	WT	WT
M25	M/35	classic	–	WT	AG	WT	WT	M77	M/26	desmoplastic	16	c.-124:GA	AA	WT	WT
M26	M/2	classic	–	WT	–	WT	WT	M78	F/4	classic	8	WT	AG	WT	WT
M27	M/65	classic	–	WT	AA	WT	WT	M79	F/9	classic	10	WT	AG	WT	WT
M28	M/39	classic	–	c.-124:GA	AG	WT	WT	M81	M/28	desmoplastic	72	c.-124:GA	AG	WT	WT
M29	F/8	classic	–	WT	GG	WT	WT	M82	F/10	classic	104	WT	AA	WT	WT
M30	F/26	classic	–	c.-146:GA	AA	WT	WT	M84	–	desmoplastic	–	WT	–	–	WT
M31	F/2	classic	–	WT	AA	WT	WT	M86	M/38	classic	–	WT	–	–	–
M32	M/33	classic	–	c.-124:GA	GG	WT	WT	M87	M/39	classic	–	c.-146:GA	–	–	–
M33	M/4	classic	–	WT	AA	WT	WT	M91	M/15	classic	–	WT	–	WT	WT
M34	F/9	classic	–	WT	AA	WT	WT	M95	M/24	classic	–	WT	AA	WT	WT
M35	M/13	classic	–	WT	–	WT	WT	M96	M/35	classic	–	c.-124:GA	–	–	WT
M36	F/18	desmoplastic	–	c.-124:GA	AG	WT	WT	M98	M/35	–	–	WT	–	–	–
M41	M/11	classic	24	WT	–	WT	WT	M100	M/6	classic	–	WT	–	–	WT
M42	F/7	classic	88	WT	–	WT	WT	M107	M/9	classic	–	WT	–	WT	WT
M43	F/18	desmoplastic	4	WT	–	WT	WT	M111	M/33	desmoplastic	–	WT	GG	WT	WT
M45	M/27	classic	24	WT	–	WT	WT	M119	–/28	desmoplastic	–	WT	GG	WT	WT
M46	F/24	classic	42	WT	AA	WT	WT	M122	M/28	desmoplastic	–	WT	AG	WT	WT

Genotypes for *hTERT* mutations: WT for both c.-124:G>A and c.-146:G>A mutations, c.-124:GA (heterozygous mutant), c.-124:AA (homozygous mutant), c.-146:GA (heterozygous mutant) and c.-146:AA (homozygous mutant). Genotypes for *hTERT* rs2853669 SNP: AA (WT), AG (heterozygous mutant) and GG (homozygous mutant). – = Data not available; m = months; OS = overall survival.

^a The same mutational status was seen in the primary and the recurrent sample of this case.

Similarly to previous reports [10, 11], *hTERT* mutations were more frequent in older patients (table 2; $p < 0.0001$), being found in only 3 patients younger than 17 years (3/35, 8.6%), whereas >50% of the adult patients presented with *hTERT* promoter mutations (18/32, 56.3%). In addition, *hTERT*-mutated tumors were more frequently in the recurrent cases ($p = 0.026$), and *hTERT* mutations were significantly enriched in the tumors located in the right cerebellar hemisphere ($p = 0.039$). No other clinicopathological features were found to be statistically significant (table 2; $p > 0.05$).

The polymorphism rs2853669 was successfully sequenced in 41 of the 69 samples, and was present in 41.5%

of the cases. Although this polymorphism has been described as modifying the survival of mutant carriers [16], we could not confirm these results in our cohort as only 6 samples presenting the variant also had survival data. No differences were seen between wild-type (WT) and mutated samples regarding overall survival (fig. 2; $p = 0.200$).

Histone Mutations Are Rare Events in Medulloblastoma

We designed primers for the hotspot regions of *H3F3A* and *HIST1H3B* and successfully sequenced 59 samples for *HIST1H3B* and 65 for *H3F3A*. None of the samples analyzed harbored any mutation on *H3F3A* or *HIST1H3B*.

Fig. 1. Representative electropherogram traces of *hTERT* Sanger sequencing from a WT sample and c.-124:G>A and c.-146:G>A mutant cases. Arrows indicate the mutated nucleotide.

Discussion

Promoter mutations of the *hTERT* gene were first described in melanoma in 2 distinct reports [13, 14]. Since then, *hTERT* promoter mutations have been described across several tumor types, and are one of the most frequent genetic alterations involved in human tumorigenesis [12, 25].

In this study, we demonstrate that 28% of our medulloblastoma samples presented *hTERT* hotspot promoter mutations, in line with previous reports (18–33%) [10, 11, 25, 26]. These mutations were more frequent in older patients ($p < 0.0001$), were not seen in any infants (aged <4 years) and were only present in 3 children of 12, 14 and 16 years of age. Previous reports have shown the same trend, with Koelsche et al. [26] reporting 3 and 65% of these mutations, respectively, in pediatric and adult patients. This is line with the literature that demonstrates clinical and molecular characteristics distinguishing pediatric and adult medulloblastomas [27]. *hTERT* mutations have been described to be associated with less metastatic medulloblastoma at diagnosis [10], and we have shown that these tumors were more prone to recurrence

Fig. 2. Kaplan-Meier survival curves for *hTERT* WT and mutant samples. No statistical differences were seen between the 2 groups ($p = 0.200$, log-rank test).

Table 2. Association of *hTERT* mutation with clinicopathological features of medulloblastoma

Characteristic	<i>hTERT</i> WT	<i>hTERT</i> mutation	p value
Age, years			
Median	11	26	<0.0001 ^a
Range	1.5–65	12–70	
n.a.	1	1	
Gender			
Female	15	7	1.000 ^c
Male	30	14	
n.a.	2	1	
Histology			
Classic	38	14	0.108 ^c
Desmoplastic	6	7	
Anaplastic	0	0	
Nodular	2	0	
n.a.	1	1	
Metastasis			
Negative	16	9	0.286 ^b
Positive	5	0	
n.a.	26	13	
Recurrence			
Negative	18	8	0.026 ^c
Positive	2	6	
n.a.	27	8	
Location			
Cerebellar vermis + 4th ventricle	26	8	0.039 ^b
Right cerebellar hemisphere	4	7	
Left cerebellar hemisphere	4	3	
n.a.	13	4	

^a Mann-Whitney U test. ^b Fisher's exact test. ^c χ^2 test.

($p = 0.026$) compared to the *hTERT* WT medulloblastomas. In addition, we also demonstrate, for the first time, that *hTERT* mutations were significantly enriched in tumors arising in the right cerebellar hemisphere ($p = 0.039$).

Mutations in histone 3 leading to K27M and G34R/G34V have been extensively reported in pediatric high-grade gliomas [18, 19]. In spite of this, not many works have reported the results of these mutations in medulloblastomas. In 2014, Huether et al. [20] studied >1,000 different pediatric cancers, 70 of which were medulloblastomas, and did not see histone mutations in this brain tumor type. Similarly, we successfully sequenced approximately 60 samples for the hotspot mutations of *HIST1H3B* and *H3F3A* and found no mutations in our samples. Currently, it is well accepted that medulloblastomas can be cytogenetically and molecularly stratified into distinct subgroups that are associated with distinct clinicopathological features [28, 29]. *hTERT* mutations have been reported more frequently in the SHH molecular subgroup [10], but further studies are needed to validate whether they are associated with particular cytogenetic and molecular subtypes.

In conclusion, we reported that hotspot *hTERT* mutations are present in approximately 1/3 of medulloblastomas cases and are associated with older patients and recurrent tumors, constituting a potential biomarker for medulloblastomas.

Acknowledgements

This study was partially supported by CNPq/Universal (475358/2011-2), Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; 2012/19590-0) and Fundação para a Ciência e Tecnologia (FCT; PTDC/SAU-ONC/115513/2009) grants to R.M.R. The project was cofinanced by Programa Operacional Regional do Norte (ON.2-O Novo Norte), Quadro de Referência Estratégico Nacional (QREN) and Fundo Europeu de Desenvolvimento Regional (FEDER). M.V.-P. is the recipient of an FCT Post-Doctorate Research Fellowship (SFRH/BPD/104290/2014).

Disclosure Statement

The authors disclose no potential conflicts of interest.

References

- 1 Bryan TM, Cech TR: Telomerase and the maintenance of chromosome ends. *Curr Opin Cell Biol* 1999;11:318–324.
- 2 Cong YS, Wright WE, Shay JW: Human telomerase and its regulation. *Microbiol Mol Biol Rev* 2002;66:407–425.
- 3 Weinrich SL, Pruzan R, Ma L, et al: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTERT. *Nat Genet* 1997;17:498–502.
- 4 Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. *Science* 1994;266:2011–2015.
- 5 Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW: Telomerase activity in human germline and embryonic tissues and cells. *Dev Genet* 1996;18:173–179.

- 6 Ozturk S, Sozen B, Demir N: Telomere length and telomerase activity during oocyte maturation and early embryo development in mammalian species. *Mol Hum Reprod* 2014; 20:15–30.
- 7 Blasco MA, Hahn WC: Evolving views of telomerase and cancer. *Trends Cell Biol* 2003; 13:289–294.
- 8 Ding D, Zhou J, Wang M, Cong YS: Implications of telomere-independent activities of telomerase reverse transcriptase in human cancer. *FEBS J* 2013;280:3205–3211.
- 9 Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. *Eur J Cancer* 1997; 33:787–791.
- 10 Remke M, Ramaswamy V, Peacock J, et al: *TERT* promoter mutations are highly recurrent in SHH subgroup medulloblastoma. *Acta Neuropathol* 2013;126:917–929.
- 11 Killela PJ, Reitman ZJ, Jiao Y, et al: *TERT* promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. *Proc Natl Acad Sci USA* 2013;110:6021–6026.
- 12 Vinagre J, Almeida A, Pópulo H, et al: Frequency of *TERT* promoter mutations in human cancers. *Nat Commun* 2013;4:2185.
- 13 Horn S, Figl A, Rachakonda PS, et al: *TERT* promoter mutations in familial and sporadic melanoma. *Science* 2013;339:959–961.
- 14 Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA: Highly recurrent *TERT* promoter mutations in human melanoma. *Science* 2013;339:957–959.
- 15 Bell RJ, Rube HT, Kreig A, et al: The transcription factor GABP selectively binds and activates the mutant *TERT* promoter in cancer. *Science* 2015;348:1036–1039.
- 16 Rachakonda PS, Hosen I, de Verdier PJ, et al: *TERT* promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. *Proc Natl Acad Sci USA* 2013;110:17426–17431.
- 17 Heaphy CM, de Wilde RF, Jiao Y, et al: Altered telomeres in tumors with *ATRX* and *DAXX* mutations. *Science* 2011;333:425.
- 18 Schwartzentruber J, Korshunov A, Liu XY, et al: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature* 2012;482:226–231.
- 19 Wu G, Broniscer A, McEachron TA, et al: Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. *Nat Genet* 2012;44:251–253.
- 20 Huether R, Dong L, Chen X, et al: The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. *Nat Commun* 2014;5:3630.
- 21 Martinho O, Gouveia A, Viana-Pereira M, Silva P, Pimenta A, Reis RM, Lopes JM: Low frequency of MAP kinase pathway alterations in *KIT* and *PDGFRA* wild-type GISTs. *Histopathology* 2009;55:53–62.
- 22 Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M: Highly prevalent *TERT* promoter mutations in bladder cancer and glioblastoma. *Cell Cycle* 2013;12:1637–1638.
- 23 Campanella NC, Celestino R, Pestana A, et al: Low frequency of *TERT* promoter mutations in gastrointestinal stromal tumors (GISTs). *Eur J Hum Genet* 2015;23:877–879.
- 24 Batista R, Cruvinel-Carlioni A, Vinagre J, et al: The prognostic impact of *TERT* promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. *Int J Cancer* 2016;139:414–423.
- 25 Huang DS, Wang Z, He XJ, et al: Recurrent *TERT* promoter mutations identified in a large-scale study of multiple tumour types are associated with increased *TERT* expression and telomerase activation. *Eur J Cancer* 2015; 51:969–976.
- 26 Koelsche C, Sahm F, Capper D, et al: Distribution of *TERT* promoter mutations in pediatric and adult tumors of the nervous system. *Acta Neuropathol* 2013;126:907–915.
- 27 Riffaud L, Hénau PL: Prognostic factors of adult medulloblastomas: a review of the literature and perspectives. *Neurochirurgie* 2016;62:46–52.
- 28 Shih DJ, Northcott PA, Remke M, et al: Cytogenetic prognostication within medulloblastoma subgroups. *J Clin Oncol* 2014;32:886–896.
- 29 Northcott PA, Shih DJ, Remke M, et al: Rapid, reliable, and reproducible molecular subgrouping of clinical medulloblastoma samples. *Acta Neuropathol* 2012;123:615–626.